Correction: Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis

Shufang Fu; Xin Wen; Fei Han; Yin Long; Gaosi Xu

doi:10.18632/oncotarget.24255

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis

PDF | How to cite

Oncotarget. 2018; 9:6658-6658. https://doi.org/10.18632/oncotarget.24255

Metrics: PDF 1965 views | ?

Shufang Fu^1,*, Xin Wen^2,*, Fei Han³, Yin Long⁴ and Gaosi Xu¹

¹ Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
² Grade 2013, School of Stomatology, Nanchang University, Nanchang, China
³ Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
⁴ Grade 2013, The Second Clinical Medical College of Nanchang University, Nanchang, China
^* Co-first authors contributted equally to this work

Published: January 15, 2018

This article has been corrected: Dr. Fu and Dr. Xu citations have been changed to affiliation 1 and affiliation 5 is now deleted.

Original article: Oncotarget. 2017; 8:89364-89374. DOI: https://doi.org/10.18632/oncotarget.19382.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24255

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis